Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) Return on Sales (2019 - 2025)

Avidity Biosciences' Return on Sales history spans 7 years, with the latest figure at 275.14% for Q4 2025.

  • For Q4 2025, Return on Sales fell 24068.0% year-over-year to 275.14%; the TTM value through Dec 2025 reached 36.4%, down 685.0%, while the annual FY2025 figure was 36.4%, 685.0% down from the prior year.
  • Return on Sales reached 275.14% in Q4 2025 per RNA's latest filing, down from 13.95% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 8.82% in Q1 2021 to a low of 275.14% in Q4 2025.
  • Average Return on Sales over 5 years is 37.23%, with a median of 20.51% recorded in 2023.
  • The largest YoY upside for Return on Sales was 2036bps in 2025 against a maximum downside of -24068bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 20.78% in 2021, then grew by 12bps to 18.22% in 2022, then crashed by -51bps to 27.51% in 2023, then dropped by -25bps to 34.46% in 2024, then tumbled by -698bps to 275.14% in 2025.
  • Per Business Quant, the three most recent readings for RNA's Return on Sales are 275.14% (Q4 2025), 13.95% (Q3 2025), and 40.72% (Q2 2025).